申请人:Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
公开号:US05705531A1
公开(公告)日:1998-01-06
1,5-Disubstituted 5a-methylperhydroinden-3a-ol derivatives of formula (I): ##STR1## where either the symbol - - - - represents a single bond, the group A is in cis configuration with respect to the 3a-hydroxy, 7a-methyl and 1-L groups, and A is (CH.dbd.CH).sub.m (CH.sub.2).sub.n OR, (CH.dbd.CH).sub.m (CH.sub.2).sub.n NR.sup.1 R.sup.2, (CH.dbd.CH).sub.m (CH.sub.2).sub.p B, OH, O(CH.sub.2).sub.q OR, O(CH.sub.2).sub.q NR.sup.1 R.sup.2 or O(CH.sub.2).sub.r B; q is an integer from 2 to 5; r is an integer from 1 to 2; or the symbol - - - - represents a double bond, A is oxygen, CH(CH.dbd.CH).sub.s (CH.sub.2).sub.n OR, CH(CH.dbd.CH).sub.s (CH.sub.2).sub.n NR.sup.1 R.sup.2 or CH(CH.dbd.CH).sub.s (CH.sub.2).sub.p B; and L is \x9bCH.dbd.C(R.sup.3)!.sub.s CH.dbd.NR.sup.4 or \x9bCH.dbd.C(R.sup.3)!.sub.s CH.sub.2 NHR.sup.4, in the E configuration, are useful for treating cardiovascular disorders such as heart failure and hypertension.
式(I)的1,5-二取代5a-甲基过氢化吲哚-3a-醇衍生物:##STR1## 其中符号- - - -表示单键,基团A与3a-羟基、7a-甲基和1-L基团的顺式构型相关,A为(CH.dbd.CH).sub.m (CH.sub.2).sub.n或(CH.dbd.CH).sub.m (CH.sub.2).sub.n NR.sup.1 R.sup.2,(CH.dbd.CH).sub.m (CH.sub.2).sub.p B,OH,O(CH.sub.2).sub.q或O(CH.sub.2).sub.q NR.sup.1 R.sup.2或O(CH.sub.2).sub.r B; q为2至5的整数; r为1至2的整数; 或符号- - - -表示双键,A为氧、CH(CH.dbd.CH).sub.s (CH.sub.2).sub.n或CH(CH.dbd.CH).sub.s (CH.sub.2).sub.n NR.sup.1 R.sup.2或CH(CH.dbd.CH).sub.s (CH.sub.2).sub.p B; L为\x9bCH.dbd.C(R.sup.3)!.sub.s CH.dbd.NR.sup.4或\x9bCH.dbd.C(R.sup.3)!.sub.s CH.sub.2 NHR.sup.4,以E构型存在,可用于治疗心血管疾病,如心力衰竭和高血压。